Regresar

Imatinib for treating newly diagnosed chronic myeloid leukemia patients

Abstract:

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the clinical benefits and harms of imatinib for treating newly diagnosed chronic myeloid leukemia patients, regardless of the leukemia phase (chronic, accelerated or blastic).

Año de publicación:

2015

Keywords:

    Fuente:

    scopusscopus

    Tipo de documento:

    Article

    Estado:

    Acceso restringido

    Áreas de conocimiento:

    • Cáncer
    • Medicina interna
    • Farmacología

    Áreas temáticas:

    • Enfermedades
    • Farmacología y terapéutica

    Contribuidores:

    Gupta P.Gupta P.
    Prof. Arturo Martí Carvajal MD MSc Ph.D iDProf. Arturo Martí Carvajal MD MSc Ph.D iD
    Daniel Simancas-RacinesDaniel Simancas-Racines
    Anand V.Anand V.
    Acevedo A.M.Acevedo A.M.
    Sola I.Sola I.
    Cardona A.F.Cardona A.F.